GO:0009223 pyrimidine deoxyribonucleotide catabolic process: Nucleotide Pool Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009223 describes the chemical breakdown of pyrimidine deoxyribonucleotides, which are deoxyribose-containing nucleotides with a pyrimidine base (thymine or cytosine) and a phosphate group.
• This catabolic process is essential for balancing deoxyribonucleotide triphosphate (dNTP) pools, preventing mutagenesis and supporting proper DNA replication and repair.
• Key enzymes include thymidylate synthase (TYMS), deoxyuridine triphosphatase (DUT), and cytidine deaminase (CDA), which catalyze steps in the breakdown or interconversion of pyrimidine deoxyribonucleotides.
• Dysregulation of pyrimidine deoxyribonucleotide catabolism is linked to megaloblastic anemia, cancer, and mitochondrial disorders.
• CRISPR knockout, point mutation, and overexpression models are powerful tools to dissect the roles of genes in this pathway and their impact on disease.
• Understanding GO:0009223 provides insights into chemotherapy resistance, antiviral drug mechanisms, and rare metabolic diseases.
Description
Pyrimidine deoxyribonucleotide catabolic process (GO:0009223) is a fundamental biological process that governs the breakdown of deoxyribonucleotides containing pyrimidine bases, such as thymine and cytosine. These molecules are essential for DNA synthesis and repair, and their catabolism ensures balanced nucleotide pools, preventing errors during DNA replication. The process involves a series of enzymatic reactions that degrade deoxyribonucleotides into their constituent bases, sugars, and phosphates, which can then be recycled or excreted. Researchers study this pathway because its dysregulation contributes to diseases ranging from megaloblastic anemia to cancer. For example, thymidylate synthase (TYMS) catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), a critical step in pyrimidine deoxyribonucleotide metabolism, and its inhibition by 5-fluorouracil leads to self-inactivation and disrupted nucleotide pools. Similarly, cytidine deaminase (CDA) contributes to thymidylate biosynthesis in Trypanosoma brucei, highlighting the pathway's importance in pathogens. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of GO:0009223, its genetic players, regulatory mechanisms, disease associations, and cutting-edge research methods.
pyrimidine deoxyribonucleotide catabolic process At A Glance
| GO ID | GO:0009223 |
|---|---|
| GO term | pyrimidine deoxyribonucleotide catabolic process |
| Ontology | biological_process |
| Synonym | pyrimidine deoxyribonucleotide breakdown, pyrimidine deoxyribonucleotide catabolism, pyrimidine deoxyribonucleotide degradation |
| Major function | Breakdown of pyrimidine deoxyribonucleotides to maintain balanced dNTP pools and prevent mutagenesis |
| Key enzymes | Thymidylate synthase (TYMS), deoxyuridine triphosphatase (DUT), cytidine deaminase (CDA) |
| Subcellular location | Cytoplasm and mitochondria |
| Related diseases | Megaloblastic anemia, cancer, mitochondrial disorders |
What Is GO:0009223?
GO:0009223, pyrimidine deoxyribonucleotide catabolic process, is defined as the chemical reactions and pathways resulting in the breakdown of a pyrimidine deoxyribonucleotide, a compound consisting of a nucleoside (a pyrimidine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar. In simpler terms, it is the process by which cells degrade deoxyribonucleotides containing pyrimidine bases, such as deoxycytidine and deoxythymidine nucleotides, into smaller molecules. This catabolic process is crucial for maintaining nucleotide homeostasis and preventing the accumulation of damaged or excess nucleotides.
Why Is pyrimidine deoxyribonucleotide catabolic process Important in Cell Biology?
The pyrimidine deoxyribonucleotide catabolic process is vital for cellular health because it regulates the availability of deoxyribonucleotide triphosphates (dNTPs) for DNA synthesis and repair. Imbalances in dNTP pools can lead to mutations, genomic instability, and cell death, contributing to cancer and other diseases. Moreover, this pathway is a target for chemotherapeutic agents like 5-fluorouracil, which disrupts thymidylate synthase and pyrimidine metabolism, and for antiviral drugs that mimic nucleotide analogs. Understanding GO:0009223 also sheds light on mitochondrial nucleotide trafficking, as defects in carriers like PNC1 can cause mitochondrial DNA depletion syndromes.
• Maintains dNTP pool balance to ensure accurate DNA replication and repair.
• Prevents accumulation of mutagenic deoxyuridine nucleotides by degrading or converting them.
• Plays a role in mitochondrial DNA maintenance through nucleotide trafficking.
• Involved in drug metabolism, including activation and inactivation of nucleoside analogs.
• Dysregulation leads to megaloblastic anemia due to impaired DNA synthesis.
• Contributes to cancer cell resistance to antimetabolite drugs like 5-fluorouracil.
• Essential for pathogen survival, as seen in Trypanosoma brucei.
• Provides targets for antimicrobial and anticancer drug development.
• Helps recycle nucleotides, reducing the energy cost of de novo synthesis.
• Its study informs personalized medicine for disorders of nucleotide metabolism.
What Happens During pyrimidine deoxyribonucleotide catabolic process?
Deamination and Phosphorolysis of Pyrimidine Deoxyribonucleotides
In simple terms: The process starts by removing an amino group or breaking the bond between the base and sugar.
Pyrimidine deoxyribonucleotide catabolism begins with the deamination of deoxycytidine nucleotides to deoxyuridine nucleotides, catalyzed by cytidine deaminase (CDA). In Trypanosoma brucei, CDA contributes to thymidylate biosynthesis by deaminating deoxycytidine to deoxyuridine, which is then phosphorylated and methylated. Alternatively, deoxyuridine triphosphatase (DUT) hydrolyzes dUTP to dUMP and pyrophosphate, preventing uracil incorporation into DNA. These initial steps are crucial for maintaining nucleotide pool fidelity and are conserved across species.
Methylation and Interconversion of Deoxyuridine Monophosphate
In simple terms: Deoxyuridine monophosphate is converted to deoxythymidine monophosphate, a key step in thymidine synthesis.
Thymidylate synthase (TYMS) catalyzes the methylation of dUMP to dTMP using 5,10-methylenetetrahydrofolate as a cofactor. This reaction is essential for thymidine biosynthesis and is a target of the anticancer drug 5-fluorouracil (5-FU), which forms a stable ternary complex with TYMS and inhibits the enzyme. Mutations in TYMS, such as E60Q, alter catalytic intermediates and affect enzyme function. The balance between dUMP and dTMP is critical; excess dUMP can be degraded further or misincorporated into DNA.
Degradation of Deoxythymidine Nucleotides
In simple terms: Deoxythymidine nucleotides are broken down into thymine, deoxyribose, and phosphate.
Deoxythymidine monophosphate (dTMP) can be dephosphorylated to thymidine, which is then cleaved by thymidine phosphorylase to thymine and 2-deoxyribose-1-phosphate. Thymine is further degraded to 3-aminoisobutyrate. This catabolic route is important for recycling thymidine and regulating dTTP levels. In cultured human cells, the pyrimidine nucleotide carrier PNC1 transports thymidine phosphates into mitochondria, where they can be catabolized or salvaged, linking catabolism to mitochondrial function.
Mitochondrial Trafficking and Compartmentalization
In simple terms: Breakdown products are moved into mitochondria for further processing or recycling.
The pyrimidine nucleotide carrier PNC1 (SLC25A33) mediates the transport of thymidine phosphates across the mitochondrial membrane, facilitating their catabolism or salvage. This trafficking is essential for mitochondrial DNA synthesis and repair, as imbalances can lead to mitochondrial DNA depletion syndromes. The compartmentalization of pyrimidine deoxyribonucleotide catabolism ensures that degradation products are available where needed and that toxic intermediates do not accumulate.
Regulation by dNTP Pool Perturbations
In simple terms: Changes in nucleotide levels can feedback to regulate the enzymes involved in breakdown.
Perturbations of dNTP pools, such as those induced by hydroxyurea or 5-FU, affect the expression of ribonucleotide reductase, a G1/S transition enzyme, in p53-mutated cells. This suggests that pyrimidine deoxyribonucleotide catabolism is coordinated with cell cycle progression and DNA repair. Additionally, the self-inactivation of TYMS by 5-FdUMP demonstrates a feedback mechanism where excess substrate analog inhibits the enzyme, reducing dTMP synthesis and shifting the balance toward catabolism.
Key Genes Involved in GO:0009223 pyrimidine deoxyribonucleotide catabolic process
The following genes and their protein products are central to the pyrimidine deoxyribonucleotide catabolic process, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TYMS | Catalyzes methylation of dUMP to dTMP; target of 5-FU | Studied for chemotherapy resistance and self-inactivation mechanisms |
| DUT | Hydrolyzes dUTP to dUMP, preventing uracil misincorporation | Target for antiviral and anticancer drug development |
| CDA | Deaminates deoxycytidine to deoxyuridine, contributing to thymidylate biosynthesis | Studied in Trypanosoma brucei and human cancers |
| PNC1 (SLC25A33) | Mitochondrial carrier for thymidine phosphates | Linked to mitochondrial DNA depletion syndromes |
| RRM1 | Ribonucleotide reductase subunit, regulates dNTP pools | Expression affected by dNTP perturbations in p53-mutated cells |
| RRM2 | Ribonucleotide reductase subunit, regulates dNTP pools | Target for cancer therapy and cell cycle studies |
| TYMP | Thymidine phosphorylase, degrades thymidine to thymine | Involved in angiogenesis and chemotherapy metabolism |
| NT5C | 5'-nucleotidase, dephosphorylates deoxyribonucleotides | Regulates nucleotide pools and mitochondrial function |
| DCK | Deoxycytidine kinase, phosphorylates deoxycytidine | Activates nucleoside analogs in cancer therapy |
| TK1 | Thymidine kinase 1, salvages thymidine | Marker of cell proliferation and cancer |
| TK2 | Thymidine kinase 2, mitochondrial salvage | Mutations cause mitochondrial DNA depletion |
| SAMHD1 | dNTP triphosphohydrolase, regulates dNTP pools | Involved in innate immunity and cancer |
| CMPK1 | UMP-CMP kinase, phosphorylates pyrimidine nucleotides | Supports nucleotide salvage and activation |
| NME1 | Nucleoside diphosphate kinase, balances NTP pools | Linked to metastasis suppression |
| NME2 | Nucleoside diphosphate kinase, balances NTP pools | Regulates dNTP pools and cell proliferation |
| GUK1 | Guanylate kinase, cross-regulates nucleotide pools | Indirectly affects pyrimidine metabolism |
| ITPA | Inosine triphosphatase, prevents toxic nucleotide accumulation | Protects against 6-mercaptopurine toxicity |
How Is pyrimidine deoxyribonucleotide catabolic process Regulated?
The pyrimidine deoxyribonucleotide catabolic process is regulated at multiple levels. dNTP pool perturbations, such as those caused by hydroxyurea or 5-fluorouracil, can alter the expression of ribonucleotide reductase (RRM1/RRM2) in a p53-dependent manner, linking catabolism to cell cycle checkpoints. Additionally, the self-inactivation of thymidylate synthase by its own product analog 5-FdUMP provides a feedback mechanism that reduces dTMP synthesis and may shift flux toward catabolism. Mitochondrial trafficking via PNC1 is regulated by cellular demand for thymidine phosphates, ensuring balanced nucleotide pools across compartments. In Trypanosoma brucei, cytidine deaminase activity is developmentally regulated, contributing to stage-specific thymidylate biosynthesis.
pyrimidine deoxyribonucleotide catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TYMS | Megaloblastic anemia, cancer, 5-FU resistance | Knockout and point mutation (E60Q) in cancer cell lines |
| DUT | Uracil misincorporation, antiviral target | Knockout in HeLa cells and overexpression for drug screening |
| CDA | Trypanosomiasis, cancer drug metabolism | Knockout in Trypanosoma brucei and human cell lines |
| PNC1 (SLC25A33) | Mitochondrial DNA depletion syndrome | Knockout and knock-in of patient mutations in fibroblasts |
| SAMHD1 | Aicardi-Goutières syndrome, cancer | Knockout in macrophages and overexpression in cancer cells |
Megaloblastic Anemia and Nucleotide Metabolism Defects
Drug-induced megaloblastic anemia can result from impaired pyrimidine deoxyribonucleotide catabolism, leading to unbalanced dNTP pools and defective DNA synthesis. For example, methotrexate and 5-fluorouracil inhibit thymidylate synthase, causing dUMP accumulation and uracil misincorporation into DNA, which triggers megaloblastic changes. Understanding these mechanisms helps optimize chemotherapy regimens and manage side effects.
Cancer and Chemotherapy Resistance
Alterations in pyrimidine deoxyribonucleotide catabolism contribute to cancer progression and resistance to antimetabolite drugs. Overexpression of thymidylate synthase (TYMS) confers resistance to 5-fluorouracil by maintaining dTMP levels despite drug inhibition. Similarly, mutations in TYMS, such as E60Q, alter catalytic efficiency and drug binding, potentially affecting clinical outcomes. Targeting catabolic enzymes like DUT or CDA may overcome resistance.
Mitochondrial DNA Depletion Syndromes
Defects in mitochondrial pyrimidine deoxyribonucleotide catabolism and trafficking can cause mitochondrial DNA depletion syndromes. Mutations in PNC1 (SLC25A33) impair thymidine phosphate transport, leading to imbalanced mitochondrial dNTP pools and mtDNA depletion. This highlights the importance of compartmentalized nucleotide metabolism in mitochondrial diseases.
Infectious Diseases and Pathogen Metabolism
Pyrimidine deoxyribonucleotide catabolism is essential for pathogen survival. In Trypanosoma brucei, cytidine deaminase contributes to thymidylate biosynthesis, and its inhibition could be a therapeutic strategy. Similarly, deoxyuridine triphosphatase (DUT) from bacteriophage PBS2 inhibits Bacillus subtilis DUT, providing insights into phage defense mechanisms.
From pyrimidine deoxyribonucleotide catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TYMS E60Q mutation alter dTMP synthesis and 5-FU sensitivity? | Point mutation knock-in in HCT116 cells |
| What is the role of DUT in preventing uracil misincorporation? | CRISPR knockout in HeLa cells |
| How does PNC1 deficiency affect mitochondrial dNTP pools? | Knockout and tagged knock-in in human fibroblasts |
| Can CDA overexpression rescue thymidylate biosynthesis in T. brucei? | Overexpression in Trypanosoma brucei |
| Does SAMHD1 regulate dNTP pools in innate immunity? | Knockout in THP-1 macrophages |
| Is TYMS self-inactivation by 5-FdUMP reversible? | Point mutation (catalytic cysteine) in recombinant enzyme |
How to Study the pyrimidine deoxyribonucleotide catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identifying dysregulated catabolic genes in cancer |
| LC-MS/MS metabolomics | dNTP and intermediate levels | Quantifying pool imbalances after drug treatment |
| Enzyme kinetics | Catalytic activity and inhibition | Characterizing TYMS mutants and inhibitors |
| X-ray crystallography | Protein structure and ligand binding | Designing DUT inhibitors |
| CRISPR knockout | Gene function loss | Studying DUT role in uracil misincorporation |
| CRISPR point mutation | Specific amino acid changes | Analyzing TYMS E60Q mechanism |
| Mitochondrial fractionation | Compartmentalized nucleotide pools | Assessing PNC1 transport activity |
| Flow cytometry | Cell cycle and apoptosis | Evaluating 5-FU sensitivity in TYMS mutants |
Genomic and Transcriptomic Profiling
RNA-seq and whole-exome sequencing can identify mutations and expression changes in genes involved in pyrimidine deoxyribonucleotide catabolism, such as TYMS, DUT, and CDA. These methods are used to study drug resistance and disease-associated variants.
Metabolomic and Flux Analysis
LC-MS/MS-based metabolomics quantifies dNTP pools and catabolic intermediates, revealing pathway flux and imbalances. Isotope tracing can track deoxyribonucleotide degradation and salvage.
Enzymatic Assays and Structural Biology
Recombinant enzyme assays measure catalytic activity of TYMS, DUT, and CDA, while X-ray crystallography and NMR provide structural insights into mechanism and inhibition. These methods are essential for drug design.
CRISPR-Cas9 Genome Editing
CRISPR knockout, point mutation, and knock-in models allow functional dissection of genes in this pathway. For example, knockout of DUT in HeLa cells reveals its role in uracil misincorporation, and point mutation of TYMS E60Q delineates catalytic intermediates.
How CRISPR Can Be Used to Study GO:0009223 pyrimidine deoxyribonucleotide catabolic process
Knockout
CRISPR knockout of genes like DUT or CDA can reveal their essential roles in pyrimidine deoxyribonucleotide catabolism. For instance, DUT knockout in HeLa cells leads to increased uracil incorporation into DNA and reduced cell viability. Similarly, CDA knockout in Trypanosoma brucei impairs thymidylate biosynthesis and growth.
Point Mutation
Point mutations can dissect catalytic mechanisms. The TYMS E60Q mutation, introduced by CRISPR, alters the enzyme's ability to form intermediates, affecting dTMP synthesis and drug sensitivity. Such models help understand how specific residues contribute to catalysis and inhibitor binding.
Knock-in
Knock-in of tagged or patient-derived mutations allows study of protein localization and function. For example, tagging PNC1 with GFP enables tracking of mitochondrial trafficking in live cells. Knock-in of disease-associated mutations in TYMS can model chemotherapy resistance.
Overexpression
Overexpression of TYMS or CDA can mimic clinical drug resistance and reveal pathway dynamics. Overexpressing TYMS in cancer cells confers resistance to 5-fluorouracil by maintaining dTMP levels. Overexpression of CDA in T. brucei enhances thymidylate biosynthesis and growth.
How EDITGENE Supports pyrimidine deoxyribonucleotide catabolic process Research
Researchers studying pyrimidine deoxyribonucleotide catabolic process-related genes often need to determine whether a candidate gene is causally involved in nucleotide pool regulation, drug response, or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for pyrimidine deoxyribonucleotide catabolic process research.
Frequently Asked Questions About pyrimidine deoxyribonucleotide catabolic process
What is pyrimidine deoxyribonucleotide catabolic process?
It is the biological process (GO:0009223) that breaks down pyrimidine deoxyribonucleotides, such as deoxycytidine and deoxythymidine nucleotides, into smaller molecules to maintain nucleotide balance.
What genes are involved in pyrimidine deoxyribonucleotide catabolic process?
Key genes include TYMS, DUT, CDA, PNC1 (SLC25A33), and RRM1/RRM2, which encode enzymes that catalyze or regulate the breakdown of pyrimidine deoxyribonucleotides.
How does thymidylate synthase relate to GO:0009223?
Thymidylate synthase (TYMS) catalyzes the methylation of dUMP to dTMP, a critical step in pyrimidine deoxyribonucleotide metabolism; its inhibition by 5-FU leads to self-inactivation and disrupted catabolism.
Why is pyrimidine deoxyribonucleotide catabolism important for cancer?
Dysregulation of this pathway can lead to dNTP pool imbalances, mutagenesis, and resistance to antimetabolite drugs like 5-fluorouracil, making it a target for cancer therapy.
What diseases are associated with defects in pyrimidine deoxyribonucleotide catabolism?
Megaloblastic anemia, mitochondrial DNA depletion syndromes, and certain cancers are linked to defects in this pathway.
How can CRISPR be used to study pyrimidine deoxyribonucleotide catabolic process?
CRISPR knockout, point mutation, and knock-in models allow functional dissection of genes like TYMS, DUT, and CDA, revealing their roles in nucleotide pool regulation and disease.
What is the role of DUT in pyrimidine deoxyribonucleotide catabolism?
Deoxyuridine triphosphatase (DUT) hydrolyzes dUTP to dUMP, preventing uracil misincorporation into DNA and maintaining genome stability.
How does PNC1 affect mitochondrial pyrimidine deoxyribonucleotide catabolism?
PNC1 (SLC25A33) transports thymidine phosphates into mitochondria, facilitating their catabolism or salvage and supporting mitochondrial DNA synthesis.
What experimental models are used to study GO:0009223?
Common models include CRISPR knockout cell lines, point mutation knock-ins, overexpression systems, and metabolomic profiling of dNTP pools.
Where can I find services to create CRISPR models for pyrimidine deoxyribonucleotide catabolism genes?
EDITGENE provides custom CRISPR knockout, point mutation, knock-in, overexpression, and library screening services for genes in this pathway.
Conclusion
The pyrimidine deoxyribonucleotide catabolic process (GO:0009223) is a critical metabolic pathway that maintains dNTP balance, prevents mutagenesis, and supports DNA replication and repair. Its dysregulation is implicated in megaloblastic anemia, cancer, and mitochondrial disorders, making it a compelling target for therapeutic intervention. Advances in CRISPR genome editing and metabolomics have accelerated functional studies of key enzymes like TYMS, DUT, and CDA, revealing new insights into drug resistance and disease mechanisms. Continued research into this pathway will likely yield novel biomarkers and treatments for nucleotide metabolism disorders.
References
- 1. Sobich J et al.. 2019. Thymidylate synthase-catalyzed, tetrahydrofolate-dependent self-inactivation by 5-FdUMP.. Arch Biochem Biophys 674:108106 PMID: 31520592
- 2. Hesdorffer CS et al.. 2015. Drug-Induced Megaloblastic Anemia.. N Engl J Med 373(17):1649-58 PMID: 26488695
- 3. Franzolin E et al.. 2012. The pyrimidine nucleotide carrier PNC1 and mitochondrial trafficking of thymidine phosphates in cultured human cells.. Exp Cell Res 318(17):2226-36 PMID: 22677043
- 4. Wadler S et al.. 1998. Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells.. Biochem Pharmacol 55(9):1353-60 PMID: 10076525
- 5. Costi PM et al.. 1996. Asparagine 229 mutants of thymidylate synthase catalyze the methylation of 3-methyl-2'-deoxyuridine 5'-monophosphate.. Biochemistry 35(13):3944-9 PMID: 8672425
- 6. Moro-Bulnes A et al.. 2019. Contribution of Cytidine Deaminase to Thymidylate Biosynthesis in Trypanosoma brucei: Intracellular Localization and Properties of the Enzyme.. mSphere 4(4) PMID: 31391279
- 7. Price AR et al.. 1975. Bacillus subtilis deoxyuridinetriphosphatase and its bacteriophage PBS2-induced inhibitor.. J Biol Chem 250(22):8804-11 PMID: 810487
- 8. Birdsall DL et al.. 1998. The separate effects of E60Q in Lactobacillus casei thymidylate synthase delineate between mechanisms for formation of intermediates in catalysis.. Protein Eng 11(3):171-83 PMID: 9613841
